Jihlava, Czechia

Jitka Fucikova

USPTO Granted Patents = 4 

Average Co-Inventor Count = 7.0

ph-index = 1

Forward Citations = 1(Granted Patents)


Company Filing History:


Years Active: 2017-2020

Loading Chart...
4 patents (USPTO):Explore Patents

Title: Jitka Fucikova: Innovator in Cancer Immunotherapy

Introduction

Jitka Fucikova is a prominent inventor based in Jihlava, Czech Republic. She has made significant contributions to the field of cancer immunotherapy, holding a total of 4 patents. Her innovative work focuses on the cryopreservation of apoptotic cancer cells, which has the potential to revolutionize cancer treatment.

Latest Patents

One of Jitka Fucikova's latest patents is titled "Cryopreservation of apoptotic cancer cells for use in immunotherapy against cancer." This patent describes a reliable method for preparing a potent vaccine useful for immunotherapy. The method involves cryopreserving a population of cells undergoing immunogenic cell death and using these cells to activate dendritic cells for immunotherapy. Specifically, the method includes cryopreserving cancer cells that are undergoing cell death, which can then be utilized to prepare a pharmaceutical composition for cancer immunotherapy.

Career Highlights

Jitka Fucikova has established herself as a key figure in her field through her innovative research and development efforts. She is currently associated with Sotio a.s., a company dedicated to advancing cancer treatment through innovative therapies. Her work has garnered attention for its potential to improve patient outcomes in cancer treatment.

Collaborations

Jitka collaborates with talented individuals in her field, including Lenka Koci and Katerina Pokorna. These collaborations enhance the research and development efforts at Sotio a.s., contributing to the advancement of cancer immunotherapy.

Conclusion

Jitka Fucikova's contributions to cancer immunotherapy through her innovative patents and collaborations highlight her role as a leading inventor in the field. Her work continues to pave the way for new treatment options for cancer patients.

This text is generated by artificial intelligence and may not be accurate.
Please report any incorrect information to support@idiyas.com
Loading…